Aztreonam avibactam resistance is an emerging microbiological concern as this combination is increasingly studied and used against difficult-to-treat Gram-negative bacteria.
Aztreonam-avibactam has a complementary mechanism: aztreonam remains stable against many metallo-beta-lactamases (MBLs), while avibactam inhibits several co-produced serine beta-lactamases. However, this mechanism does not eliminate the possibility of resistance. Recent studies have identified alterations involving PBP3, AmpC beta-lactamases, porins and efflux systems that can reduce susceptibility.
Understanding these mechanisms is important for interpreting susceptibility results, surveillance data and the continued development of aztreonam-avibactam.
What Is Aztreonam Avibactam Resistance?
Aztreonam-avibactam resistance occurs when a bacterial isolate has reduced susceptibility to the combination to a degree that meets the applicable resistant breakpoint.
Resistance can develop through different biological pathways.
These include:
- alteration of the antibiotic target
- modification or overproduction of beta-lactamases
- reduced outer-membrane permeability
- increased antibiotic efflux
- combinations of multiple resistance mechanisms
Importantly, resistance is not necessarily caused by a single mutation.
In some organisms, several changes can work together to substantially reduce aztreonam-avibactam activity.
Why Can Aztreonam Avibactam Become Resistant Despite Avibactam?
Avibactam inhibits several serine beta-lactamases, but it does not inhibit every beta-lactamase class.
For example, avibactam does not directly inhibit Class B MBLs such as NDM, VIM and IMP.
The combination instead relies on:
Aztreonam → stability against MBL hydrolysis
and
Avibactam → inhibition of susceptible serine beta-lactamases
This creates a useful complementary mechanism, but bacteria can still develop resistance through changes outside this specific inhibitor-enzyme interaction.
The 2026 IDSA guidance describes this distinction clearly for NDM-producing Enterobacterales: aztreonam is stable to NDM, while co-produced ESBLs, AmpCs and OXA-type enzymes can hydrolyze aztreonam and are inhibited by avibactam.
Major Aztreonam Avibactam Resistance Mechanisms
Current evidence identifies several major mechanisms:
| Resistance mechanism | How it can affect activity |
|---|---|
| PBP3 alteration | Changes the aztreonam target |
| AmpC alterations | Can reduce susceptibility despite avibactam |
| Beta-lactamase variants | May alter inhibitor/antibiotic interaction |
| Porin changes | Reduce antibiotic entry |
| Efflux overexpression | Increases antibiotic removal |
| Multiple mechanisms | Can produce higher-level resistance |
A 2026 review highlights PBP3 modifications, beta-lactamase variants, porin mutations and efflux alterations as important resistance pathways.
PBP3 Alterations and Aztreonam Avibactam Resistance
PBP3 is the principal bacterial target of aztreonam.
Therefore, changes in PBP3 can affect the ability of aztreonam to bind its target.
This is particularly important in Escherichia coli.
A study of clinical E. coli isolates found that resistant isolates frequently carried PBP3 insertions, including YRIK or YRIN insertions, together with other resistance determinants.
These findings illustrate an important concept:
Even when beta-lactamases are inhibited, changes at the antibiotic’s target can reduce susceptibility.
PBP3 alterations should therefore be considered when investigating unusual aztreonam-avibactam susceptibility patterns.
AmpC and Aztreonam Avibactam Resistance
AmpC is another important part of the resistance picture.
Avibactam inhibits many AmpC enzymes, but resistance can emerge when the enzyme itself changes or when its expression increases sufficiently.
A particularly relevant 2026 study investigated aztreonam-avibactam-resistant Enterobacter xiangfangensis mutants.
The researchers identified combinations involving:
- AmpC structural mutations
- ampD mutations
- mutations affecting the ampC attenuator region
- increased ampC expression
The combination of these changes produced progressively higher aztreonam-avibactam MICs.
This demonstrates that resistance can involve both structural and regulatory changes in the beta-lactamase system.
PBP3 + AmpC: Why Multiple Mechanisms Matter
Some of the most important resistance patterns are not caused by one mechanism alone.
For example:
PBP3 alteration + AmpC production
can provide more resistance than either mechanism alone in certain bacterial backgrounds.
A study of NDM-producing and NDM/OXA-48-like-producing Enterobacterales in Singapore found that aztreonam-avibactam resistance occurred in E. coli and Providencia species, with resistant E. coli isolates showing PBP3 insertions in association with CMY-type AmpC beta-lactamase.
This is important because it shows why simply identifying an MBL does not completely explain aztreonam-avibactam susceptibility.
Porin Changes and Aztreonam Avibactam Resistance
Porins are channels in the bacterial outer membrane that influence the movement of molecules into Gram-negative bacteria.
Changes that reduce porin expression or alter porin structure can decrease antibiotic penetration.
In E. coli, changes involving OmpC and OmpF have been associated with decreased susceptibility to aztreonam-avibactam.
Therefore, even when aztreonam remains chemically stable and avibactam inhibits relevant beta-lactamases, insufficient intracellular antibiotic exposure can still contribute to resistance.
Efflux Pumps and Aztreonam Avibactam Resistance
Gram-negative bacteria can also reduce intracellular antibiotic concentrations through active efflux.
One example is the AcrAB-TolC efflux system in Enterobacterales.
Research examining aztreonam-avibactam-resistant E. coli isolates identified alterations involving efflux-related pathways. Experimental testing also suggested that permeability and efflux contributed to decreased susceptibility in some isolates.
This means resistance is not exclusively a beta-lactamase problem.
The bacterial envelope and transport systems can also influence the final susceptibility phenotype.
Aztreonam Avibactam Resistance in NDM-Producing Enterobacterales
NDM-producing Enterobacterales are an important target population for aztreonam-avibactam.
NDM is an MBL, and aztreonam is stable against NDM-mediated hydrolysis.
However, NDM-producing bacteria frequently carry additional resistance determinants.
These may include:
- ESBLs
- AmpC enzymes
- OXA-type enzymes
- PBP3 alterations
- permeability changes
- efflux mechanisms
The 2026 IDSA guidance reports that more than 95% of NDM-producing Enterobacterales in surveillance datasets were susceptible to aztreonam-avibactam using the CLSI susceptible breakpoint, while also emphasizing that AST remains important.
So:
NDM-positive ≠automatically resistant
and
NDM-positive ≠automatically susceptible.
The actual isolate’s susceptibility phenotype still matters.
Aztreonam Avibactam Resistance in NDM/OXA-48-Like Organisms
Dual-carbapenemase producers can create additional resistance complexity.
For example, NDM/OXA-48-like-producing E. coli may combine:
- MBL activity
- additional serine beta-lactamase activity
- PBP3 alterations
- permeability changes
A 2025/2026 Singapore surveillance study found higher aztreonam-avibactam resistance among certain NDM/OXA-48-like-producing E. coli isolates, particularly isolates carrying PBP3 insertions and CMY-type AmpC.
This reinforces why resistance mechanism testing and phenotypic AST are complementary.
Does Avibactam Resistance Mean Aztreonam Avibactam Will Always Fail?
Not necessarily.
A laboratory finding of an altered beta-lactamase does not automatically translate into clinical failure.
The final interpretation depends on:
- organism
- MIC
- applicable breakpoint
- resistance mechanism
- infection site
- drug exposure
- patient factors
- clinical context
In-vitro resistance findings are therefore extremely important for surveillance and microbiology, but they should not be interpreted as a direct prediction of an individual clinical outcome.
Aztreonam Avibactam Susceptibility Testing
Because resistance mechanisms can be complex, susceptibility testing remains essential.
Current laboratory approaches include:
- broth microdilution
- disk diffusion
- validated gradient diffusion methods
- other validated AST platforms where applicable
The result should be interpreted using the appropriate current breakpoint system.
Our dedicated article on Aztreonam Avibactam Susceptibility Testing covers MICs, breakpoints and testing methods in more detail.
The 2026 IDSA guidance also emphasizes that identification of a carbapenemase gene does not eliminate the need for susceptibility testing.
Aztreonam Avibactam Resistance and Pseudomonas aeruginosa
Resistance mechanisms can differ substantially between Enterobacterales and non-fermenting Gram-negative organisms.
The 2026 IDSA guidance states that aztreonam-avibactam has limited activity against MBL-producing Pseudomonas aeruginosa, and CLSI/FDA susceptibility breakpoints are not available for this organism.
For MBL-producing P. aeruginosa, IDSA identifies cefiderocol as the preferred option, while noting limitations in the available clinical outcome data.
This is another reason not to generalize Enterobacterales susceptibility data to every Gram-negative pathogen.
Can Aztreonam Avibactam Resistance Develop During Treatment?
Selection of resistant subpopulations is a recognized concern with antimicrobial therapy.
When bacteria are exposed to antibiotic concentrations that select for organisms carrying advantageous resistance mechanisms, resistant populations may emerge.
For aztreonam-avibactam, potential pathways include:
- PBP3 changes
- beta-lactamase evolution
- increased AmpC expression
- porin loss
- efflux changes
Recent experimental work in Enterobacter demonstrated how combinations of AmpC structural and regulatory mutations can drive high-level resistance.
This makes antimicrobial stewardship and microbiological surveillance important components of responsible use.
What Does 2026 Research Tell Us About Aztreonam Avibactam Resistance?
The evidence base has become more detailed in 2026.
A recent review concluded that resistance mechanisms vary by bacterial genus and can involve:
- PBP3 modifications
- beta-lactamase variants
- porin mutations
- efflux alterations.
Another 2026 review similarly emphasizes emerging resistance involving PBP3 insertions, porin mutations and efflux-pump overexpression.
Meanwhile, experimental work has identified specific AmpC/ampD regulatory combinations that can produce high-level aztreonam-avibactam resistance in Enterobacter.
Together, these findings show that resistance should be viewed as a multifactorial biological process, rather than as a single beta-lactamase problem.
Aztreonam Avibactam Resistance vs MBL Resistance
These terms are related but not identical.
MBL resistance
Refers specifically to resistance mediated by metallo-beta-lactamases such as:
- NDM
- VIM
- IMP
Aztreonam-avibactam resistance
Refers to reduced susceptibility to the combination itself.
An isolate can carry an MBL and still be susceptible to aztreonam-avibactam.
Conversely, an isolate can develop aztreonam-avibactam resistance through mechanisms such as PBP3 changes or AmpC alterations.
Therefore:
MBL detection is a resistance-mechanism result.
Aztreonam-avibactam AST is a susceptibility result.
They should not be treated as interchangeable.
Aztreonam Avibactam Resistance and Meblanios
Meblanios is an Aztreonam and Avibactam injection from AIONIOS Pharma.
The resistance mechanisms discussed here relate to the aztreonam-avibactam combination as a scientific and microbiological topic.
For product information, readers can visit the dedicated Meblanios product page.
For supporting scientific topics, link this article to:
- Aztreonam and Avibactam
- Aztreonam Avibactam Mechanism of Action
- MBL Resistance and Aztreonam Avibactam
- Aztreonam Avibactam Susceptibility Testing
- Aztreonam Avibactam Clinical Trials
This creates a clean topical relationship without creating another Meblanios-specific resistance article.
Frequently Asked Questions
What are the main aztreonam avibactam resistance mechanisms?
Important mechanisms include PBP3 alterations, beta-lactamase changes, AmpC overexpression or structural changes, porin alterations and efflux-pump activity.
Can PBP3 mutations cause aztreonam-avibactam resistance?
Yes. PBP3 alterations, including insertions and other changes, have been identified in aztreonam-avibactam-resistant Enterobacterales.
Can AmpC cause aztreonam-avibactam resistance?
Yes. Recent research has shown that structural AmpC changes combined with regulatory mutations affecting ampC expression can produce high-level resistance in Enterobacter.
Does NDM cause aztreonam-avibactam resistance?
NDM itself does not automatically make an isolate resistant to aztreonam-avibactam. Aztreonam is stable against NDM, while avibactam inhibits susceptible co-produced serine beta-lactamases. Additional mechanisms can nevertheless cause resistance.
Is aztreonam-avibactam resistance the same as MBL resistance?
No. MBL production is one resistance mechanism, while aztreonam-avibactam resistance describes the susceptibility phenotype of the organism to the combination.
Should susceptibility testing be performed when an MBL is detected?
Yes. Carbapenemase detection provides important mechanistic information but does not replace antimicrobial susceptibility testing.
Conclusion
Aztreonam avibactam resistance is a multifactorial phenomenon involving more than beta-lactamase production alone.
The most important mechanisms currently described include PBP3 alterations, AmpC and other beta-lactamase changes, porin dysfunction and efflux-pump activity. Recent 2026 research has also demonstrated how combinations of structural and regulatory AmpC mutations can produce substantial increases in aztreonam-avibactam MICs.
For this reason, MBL detection, molecular resistance testing and phenotypic susceptibility testing provide complementary information.
As resistance surveillance develops, keeping susceptibility testing aligned with current breakpoint standards and interpreting results in the context of the organism and resistance mechanism will remain important.